NEW YORK, September 13, 2009

Abstract

Over the last few years, most of the innovations in pharmaceutical development have been only incremental — for most indications, there are significant therapy options available and it is unlikely that a radically better “wonder drug” will become available soon. In this white paper, Sanjay Parikh, PhD, Director, Indegene Lifesystems, discusses the essence of “claims-based R&D” that lies in taking a backward “market to lab” approach so as to ensure that the CDP is designed to address specific unmet market needs. It also involves the systematic benchmarking of a product’s CDP to current and future competition while continuously evaluating scientific and market threats and opportunities.

This white paper will help you understand

• How consumer, scientific and competitor insights can be used to align pharmaceutical R&D to the unmet needs of the market.
• The role of a robust clinical development plan and clinical operations plan in achieving a TPP, superior to that of the competitor.
• How “claims-based R&D” can be incorporated in an organization’s strategic framework at significantly reduced costs

Click on the link below to view the white paper

http://www.fiercebiotech.com/whitepapers/competitive-benchmarking-cdps-optimize-trial-designs-and-clinical-operations